A detailed history of Israel Englander (Millennium Management LLC) transactions in Immatics N.V. stock. As of the latest transaction made, Millennium Management LLC holds 50,000 shares of IMTX stock, worth $459,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,000
Previous 15,888 214.7%
Holding current value
$459,500
Previous $166,000 250.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$9.78 - $13.49 $415,425 - $573,014
42,477 Added 267.35%
58,365 $678,000
Q1 2024

May 15, 2024

BUY
$10.23 - $12.94 $162,534 - $205,590
15,888 New
15,888 $166,000
Q2 2023

Aug 14, 2023

BUY
$5.92 - $12.72 $6.87 Million - $14.8 Million
1,160,586 Added 457.32%
1,414,365 $16.3 Million
Q1 2023

May 15, 2023

BUY
$6.74 - $9.44 $663,034 - $928,641
98,373 Added 63.3%
253,779 $1.75 Million
Q4 2022

Feb 14, 2023

SELL
$8.05 - $11.58 $555,152 - $798,591
-68,963 Reduced 30.74%
155,406 $1.35 Million
Q3 2022

Nov 14, 2022

SELL
$3.31 - $13.06 $1.13 Million - $4.47 Million
-342,383 Reduced 60.41%
224,369 $2.24 Million
Q2 2022

Aug 15, 2022

BUY
$6.0 - $9.37 $3.18 Million - $4.96 Million
529,325 Added 1414.29%
566,752 $4.94 Million
Q1 2022

May 16, 2022

BUY
$6.64 - $12.85 $89,640 - $173,475
13,500 Added 56.42%
37,427 $299,000
Q3 2021

Nov 15, 2021

SELL
$11.58 - $15.46 $614,863 - $820,879
-53,097 Reduced 68.94%
23,927 $311,000
Q2 2021

Aug 16, 2021

BUY
$10.43 - $12.81 $803,360 - $986,677
77,024 New
77,024 $894,000
Q1 2021

May 17, 2021

SELL
$10.24 - $14.6 $1.05 Million - $1.49 Million
-102,309 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$9.67 - $12.05 $802,503 - $1 Million
82,989 Added 429.55%
102,309 $1.1 Million
Q3 2020

Nov 16, 2020

BUY
$8.73 - $15.15 $168,663 - $292,698
19,320 New
19,320 $205,000

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $701M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.